In recognition of #AMLWorldAwarenessDay, the NCRI AML18 trial reports DAGO2 induction is superior to CPX-351 for older patients without adverse-risk cytogenetics. 🩺 With @bloodjournals.hematology.org.

Read the review: https://bit.ly/3OEKzQ7

#AMLsm #KnowAML #Leukemia

Bispecific Antibodies May Reduce Relapse Risk Following HCT in B-Cell Lymphomas Using bispecific antibodies targeting CD20 and CD3 does not reduce efficacy or increase toxicity among patients with relapsed or refractory non-Hodgkin B-cell lymphomas undergoing HCT.

The use of bispecific antibodies targeting CD20 and CD3 does not reduce efficacy or increase toxicity among patients with relapsed or refractory #NonHodgekinLymphoma #BHNL (b-cell) undergoing allogeneic hematopoietic cell transplantation (HCT).

https://bit.ly/48W2qca

#HemOnc

Trial Results Show Majority of Patients With CLL Achieve uMRD With VenO Researchers determined fixed-duration VenO resulted in high rates of uMRD by 15 months compared with FCR or BR among patients with CLL.

In an exploratory analysis of uMRD in peripheral blood at 15 months, uMRD <10-5 was achieved by 76.3% in the VenO group compared with 43.0% in the FCR/BR group.

According to a study published in Blood. https://bit.ly/4dQVDE3

#HemOnc

#WorldHemophiliaDay: RCT data confirms ultrasound superiority for hemarthrosis. Results show 93.3% pain reduction and significant flexion recovery (p=0.011). 📊 With @rarediseaseadvisor.bsky.social.

Read the review: https://bit.ly/4tNKTLi

#Hematology #Hemophilia

#WorldHemophiliaDay: Meta-analysis data (n=2,995) confirms 79.3% of HRQoL heterogeneity in pediatric patients is explained by prophylactic treatment access. 📊

Read the review: https://bit.ly/4cA4Qyv

#Pediatrics

DAGO2 Superior to CPX-351 for Older Patients With Non-Adverse-Risk AML Researchers determined a DAGO2 therapy regimen results in superior survival in older patients with non-adverse-risk AML compared with CPX-351.

Superior survivorship in older patients with #AML has been found when treated with DAGO2 versus CPX-351.

Researchers have been working on several different trials to improve outcomes for older patients with AML; more on this study: https://bit.ly/3OEKzQ7

#HemOnc

Long-Term Remission Possible With MRD-Guided Azacitidine for MDS and AML Researchers determined some patients with MDS or AML who were positive for MRD after initial treatment demonstrated long-term remission with up to 2 years of azacitidine.

New research from Blood:

Long-term remission for patients with #MDS and #AML who are also positive for #MRD was found with up to 2 years of treatment with azacitidine.

https://bit.ly/4c9onqm

#HemOnc

Addressing Disproportionate Burnout Among SCD Specialists Hematologists who specialize in the treatment of sickle cell disease (SCD) experience significantly higher rates of burnout.

Hematologists who specialize in the treatment of #SickleCellDisease experience significantly higher rates of burnout. Why is that?

https://bit.ly/4mwj6Ni

Improving Health-Related Quality of Life for Children With Hemophilia Researchers determined family, sports, and school domains significantly impacted health-related quality of life of children with hemophilia.

How can clinicians address the negative impacts hemophilia has on a patient's overall wellbeing and quality of life?

Pari Singh, MD, assessed the factors affecting health-related quality of life of children with hemophilia in India. Read more about their research below:

https://bit.ly/4cA4Qyv

Psychological and Economic Burden Pertinent to Patient Outcomes in CML Researchers determined care for patients with CML should be expanded to include a holistic assessment of the psychological burden, economic stress, and impact on QoL.

Should holistic assessments of the psychological burden and economic stress of cancer be considered?

Results from a study of patients with chronic myeloid leukemia argue, yes.

https://bit.ly/4tGs0Kt

#HemOnc #CanSky

Unsigned Chemotherapy Orders Delays Treatment in Hematologic Cancers Researchers determined unsigned chemotherapy orders may contribute to delays in initiating treatment among patients with hematologic cancers.

Unsigned chemotherapy orders may contribute to delays in initiating treatment among patients with hematologic cancers, according to findings presented at the 2026 NCCN Annual Conference.

https://bit.ly/48xyR0l

#HemOnc #NCCN2026

IV Iron Dextran Cost Effective for Iron-Deficiency Anemia With Heavy Menstrual Bleeding Researchers determined first-line IV iron dextran is cost effective in treating iron-deficiency anemia in women with heavy menstrual bleeding.

A study in @bloodadvances.bsky.social found that first-line IV iron dextran was cost effective in treating iron-deficiency anemia in women with heavy menstrual bleeding.

https://bit.ly/3OlHcNX

Acute Heart Failure Associated With Worse Outcomes After HSCT Researchers determined patients who develop acute heart failure during HSCT demonstrated worse outcomes, including longer hospital stays and higher mortality rates.

ICYMI: Patients who develop acute heart failure during hematopoietic stem cell transplantation demonstrated worse outcomes. This is according to a poster presented at the 2026 NCCN Annual Conference that was held March 27-29th in Orlando.

https://bit.ly/4mhcxxR

#NCCN2026

On #WorldHealthDay, data confirm #hemophilia notably reduces pediatric HRQoL. Physical health and school attendance remain the primary domains of impairment in children.

Read the review: https://bit.ly/4cA4Qyv

#HemOnc #MedEd #Hematology

HLA-A*01 Genotype Linked With Inferior Survival in Immune Checkpoint Inhibitor Setting Researchers determined an HLA-A*01 genotype has been linked with inferior OS and PFS among patients receiving immune checkpoint inhibitors.

Research presented at #ESMOTAT26 found that the human leukocyte antigen class 1 (HLA-A*01) genotype has been linked with inferior overall survival and progression-free survival among patients receiving immune checkpoint inhibitors.

bit.ly/4mo2zuz

@myesmo.bsky.social #HemOnc

Acute Heart Failure Associated With Worse Outcomes After HSCT Researchers determined patients who develop acute heart failure during HSCT demonstrated worse outcomes, including longer hospital stays and higher mortality rates.

According to a poster presented at the 2026 NCCN Annual Conference, Patients who develop acute heart failure (AHF) during hematopoietic stem cell transplantation (HSCT) demonstrated worse outcomes, including longer hospital stays and higher mortality rates.

https://bit.ly/4mhcxxR

Clinical Quiz: National Alliance of Sickle Cell Centers Consensus Recommendations on SCD Screening and Management - Hematology Advisor Take this quiz to test your knowledge on the National Alliance of Sickle Cell Centers’ consensus recommendations on SCD health maintenance.

Test clinical knowledge on the NASCC consensus for #SCD. Topics include TCD screening for stroke prevention, penicillin prophylaxis, and hydroxyurea protocols. Accuracy is vital for outcomes. 🩺

Read the review: https://bit.ly/4sjIJ5d

#Quiz #SickCellDisease

Could a Multicomponent Strategy Increase HPV Vaccination Rates in the Primary Care Setting? - Oncology Nurse Advisor Investigators sought to increase HPV vaccination rates in children by age 13 years through the use of a multicomponent strategy in pediatric primary care practices.

"A multicomponent intervention designed to increase HPV vaccination rates in children did not show significant improvements in the short run; however..." Published in @jamanetworkopen.com.

https://bit.ly/47GZb80

#HPV

Long-Term aHTA May Increase Risk for High-Grade CRS Researchers determined patients taking antihypertensive drugs for extended periods may be at elevated risk for high-grade CRS.

Patients #aHTA drugs for extended periods may be at elevated risk for high-grade #cytokineReleaseSyndrome.

https://bit.ly/4ce6ENs

#CRS #ESMOTAT26

Novel Patient-Reported eDiary Validated for Assessing Sickle Cell Pain Crises Researchers determined an electronic diary demonstrated strong content validity in tracking home-managed sickle cell pain crises in adolescents and adults with SCD.

A novel patient-reported outcome tool designed to capture home-managed sickle cell pain crises demonstrated strong content validity in adolescents and adults with #sickleCellDisease.

https://bit.ly/4lOwITz

#SCD #SickleCellDisease

Ultrasensitive ctDNA-MRD Validated Following First-Line Therapy in LBCL Researchers determined detecting ctDNA-MRD with the PhasEd-Seq is a valid approach in LBCL and warrants further integration of MRD into assessments involving clinical responses.

Ultrasensitive ctDNA assays for #MRD detection show 100% specificity in predicting LBCL relapse. Phased variants outperform trackable mutations for early identification of treatment failure. From @ascopost.bsky.social.

Read the review: https://bit.ly/4t6hoEj

#lymsm #MedEd #LBCL

Cancer Continues to Disrupt Employment and Career Trajectories in Young Adult Survivors Researchers determined employment disruptions remain a persistent and underrecognized consequence of cancer for many young adult survivors.

#Employment disruptions remain a persistent and underrecognized consequence of #cancer for many young adult survivors, even a decade after diagnosis. Published in @ascopost.bsky.social.

https://bit.ly/4t4rxRK

#CancerCare

Researchers Develop Externally Validated Prognostic Model for Newly Diagnosed Follicular Lymphoma Researchers determined the FLIPI24 prognostic model performs excellently in cases of newly diagnosed follicular lymphoma.

The FLIPI24 prognostic model performs excellently in cases of newly diagnosed #follicularLymphoma, demonstrating superiority over existing models. Published in @ascopost.bsky.social.

https://bit.ly/4uTbTuo

#lymsm

Implementing Public Health Policy to Improve Bleeding Disorder Management Feasible in Less-Resourced Countries Real-world data from Brazil demonstrate it is feasible to implement a public health policy that improves the management of IBDs in less-resourced countries.

It is feasible to implement a public health policy that improves the management of #IBDs in less-resourced countries, as demonstrated by real-world success in Brazil. Published in @bloodjournals.hematology.org.

https://bit.ly/4uQ6moh

#BleedingDisorders

Patients With MPN Have Greater Risk of Developing Second Malignancies Researchers determined patients with a Philadelphia chromosome-negative MPN were at a greater risk of having second malignancies than the general population.

Patients with a Philadelphia chromosome-negative #myeloproliferativeNeoplasm were found to be at a greater risk of having second malignancies than was observed in the general population. Reported in @ascopost.bsky.social.

https://bit.ly/41lSHI2

#MPN

Transfusion Approaches Have Different Effects on Inflammatory and Angiogenic Pathways in SCD Researchers determined exchange transfusion and top-up transfusions may display different effects on inflammatory and angiogenic pathways in patients with SCD.

Study identifies distinct impacts of blood transfusions on #SCD. Chronic regimens reduce inflammatory and angiogenic markers, while acute transfusions may increase specific pro-inflammatory cytokines.

Read the review: https://bit.ly/3NmK7FN

#Hematology #BloodTransfusion #SickleCellDisease

SAARC Region Shows Increasing Burden in Hematologic Malignancy Incidence and Mortality Researchers determined countries in the SAARC region demonstrate an increasing burden related to hematologic malignancies.

SAARC nations account for 9.3% of global cancer incidence but 12% of mortality. Elevated mortality-to-incidence ratios (0.65 vs 0.49 globally) indicate critical gaps in #hematologic care.

Read the review: https://bit.ly/4t5Zh1b

#cancerMortality #HemOnc

As the Global Burden of Hodgkin Lymphoma Decreases, Disparities Persist Incidence of Hodgkin lymphoma has decreased globally and is projected to continue to decrease through 2035, but lower SDI regions demonstrated more modest decreases in HL incidence and mortality.

Analysis of #HodgkinLymphoma burden from 1990–2019 reveals a 31.2% increase in global cases. Significant disparities persist in mortality rates and access to care across varying sociodemographic regions.

Read the review: ➡️ https://bit.ly/4uMFfui

#lymsm #globalhealth #lymphoma

Understanding CHIP and CCUS With Lachelle D. Weeks, MD, PhD Lachelle D. Weeks, MD, PhD elucidates the complex and still-emerging field of clonal hematopoiesis, specifically regarding clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia o...

Dr Weeks discusses a relatively new area of research in #hematologyOncology: CHIP and CCUS.

https://bit.ly/4bDvNAH

#HemOnc

ML-Based, Treatment-Specific Risk Models Improve Prognostic Stratification in Ven-Aza–Treated AML Researchers determined a machine learning–based risk stratification approach tailored specifically to venetoclax plus azacitidine therapy improves prognostic classification for patients with newly diagnosed AML.

A machine learning–based risk stratification approach tailored specifically to venetoclax plus azacitidine therapy improves prognostic classification for patients with newly diagnosed #acuteMyeloidLeukemia. Published in @ascopost.bsky.social.

Read more here: ➡️ https://bit.ly/4sqtfNG

#AML #leusm